Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-10-28
1999-06-15
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3141
Patent
active
059122595
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
This invention concerns a method for treating and preventing neurodegenerative disorders such as stroke, head trauma, multiple sclerosis, and Alzheimer's disease, by administering a thiazolidinone.
BACKGROUND OF THE INVENTION
Neurodegenerative diseases are becoming more prevalent with the aging population. The most common neurodegenerative disorders include stroke and head trauma, and chronic disorders such as multiple sclerosis and Alzheimer's disease. Various causes have been postulated for many of these disorders, but no direct cause of neurodegeneration per se has been identified. For example, Alzheimer's disease, a condition afflicting millions of individuals, and becoming more common with the aging population, is a heterogeneous disease, clinically, genetically, pathologically, and biochemically. Diagnosis is based on the exclusion of other possible causes of dementia, and is more difficult in the early stages of the disease. Patients with Alzheimer's disease show a progressive loss of cognitive function beginning with seemingly benign memory lapses and culminating in severe dementia involving all domains of cognitive function. To date, only one therapeutic approach has been approved for the clinical treatment for Alzheimer's disease, that being acetylcholinesterase inhibitors. However, their clinical effectiveness is somewhat limited.
We have now discovered that neurodegenerative disorders such as Alzheimer's disease, stroke, head trauma, and multiple sclerosis can be treated with a thiazolidinone, specifically a compound known as olidinone, or a pharmaceutically acceptable salt thereof. The compound is described in U.S. Pat. No. 5,143,928. It inhibits the activities of both cyclooxygenase and 5-lipoxygenase, and is useful as an anti-inflammatory agent. An object of this invention is to provide a method for treating and preventing neurodegenerative disorders utilizing the compound.
SUMMARY OF THE INVENTION
This invention provides a method for treating and preventing neurodegenerative disorders comprising administering to a patient in need of treatment an effective amount of lidinone or a pharmaceutically acceptable salt thereof. A preferred embodiment utilizes the methanesulfonate salt. Also preferred is the Z geometric isomer. Another preferred embodiment is prevention or treatment of Alzheimer's disease. In another embodiment, the neurodegenerative disorder prevented or treated is multiple sclerosis. In still another embodiment, the disorder treated is stroke or head trauma.
DETAILED DESCRIPTION OF THE INVENTION
The term "thiazolidinone" means the specific compound named above, its pharmaceutically acceptable salts, and its individual geometric isomers. The thiazolidinone to be employed in the method of this invention is prepared and formulated as described in U.S. Pat. No. 5,143,928 which is incorporated herein by reference. All that is required to practice the method of this invention is to administer an effective amount of the thiazolidinone to a subject suffering from a neurodegenerative disorder or at risk of developing such disorder and in need of treatment. The term "effective amount" means the dosage of the thiazolidinone needed to elicit a positive clinical response to the neurodegenerative disorder or to prevent the disorder without causing unacceptable adverse side effects. While the specific dosage will vary somewhat depending upon the severity of the disorder being treated, the individual patient, and the discretion of the attending medical practitioner, the dosage that generally is effective to treat and prevent neurodegenerative disorders will be from about 0.5 to about 500 mg of thiazolidinone per day of treatment. Commonly utilized dosage regimes are from about 1 to 50 mg, administered from one to about four times a day. A preferred route of administration is oral, although parenteral and transdermal administration are also contemplated. Controlled release formulations, particularly in the form of skin patches and the like, are particularly well su
Carroll, Jr. Richard Thomas
Dyer Richard Dennis
Robichaud Lillian Jane
Shivers Brenda DeRae
Ashbrook Charles W.
Criares Theodore J.
Warner-Lambert & Company
LandOfFree
Method for treating and preventing neurodegenerative disorders b does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating and preventing neurodegenerative disorders b, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating and preventing neurodegenerative disorders b will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-402798